
Sherwin-Williams delivered a strong Q2 2026, with double-beat results and 7.6% year-over-year revenue growth to $6.79B. SHW raised full-year 2026 EPS guidance to $11.80–$12.20, reflecting robust pricing power and segment gains, despite integration and margin headwinds from Suvinil. My free cash flow valuation model indicates SHW trades at a 12% discount to fair value, supporting a continued Buy rating.










